Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr

Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore

Caplin Point announces completion of unannounced USFDA inspection

The inspection was concluded with zero observations

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

Gland Pharma posts 16% revenue growth in Q1 FY25

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Briefs: Indoco Remedies and Alembic Pharmaceuticals

Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe

Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power

The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)